Introduction: Cognitive-behavioral therapy (CBT) for obsessive-compulsive disorder (OCD) has proven its efficacy in randomized controlled trials (RCTs). Objective: To test generalizability to routine care settings, we conducted an effectiveness study to provide naturalistic outcome data and their predictors. Methods: Pre-post changes in symptoms and impairment as well as response rates were determined in a naturalistic OCD sample (intention-to-treat, ITT, n = 393). Patients received individual CBT for OCD adopting an exposure-based, non-manualized treatment format. Linear and logistic regression analyses were applied to identify associations of sociodemographic and clinical variables with symptom change. Results: Effect size in ITT patients amounted to d = 1.47 in primary outcome (Yale-Brown Obsessive-Compulsive Scale, Y-BOCS). Remission rates were 46.3% (ITT), 52.0% (completers), and 18.2% (non-completers). The rates of treatment response without remission, no change, and deterioration in the ITT sample were 13.2, 38, and 3%, respectively. Initial symptom severity, comorbid personality disorder, and unemployment were associated with a poorer outcome, and previous medication with a better outcome. Comorbid depressive and anxiety disorders as well as other clinical or sociodemographic variables showed no effects on symptom change. Conclusions: Outcomes in this large observational trial in a naturalistic setting correspond to available RCT findings suggesting that CBT for OCD should be strongly recommended for dissemination in routine care. Targets for further research include early prediction of non-response and development of alternative treatment strategies for patients who respond insufficiently.

1.
Ruscio
AM
,
Stein
DJ
,
Chiu
WT
,
Kessler
RC
.
The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication
.
Mol Psychiatry
.
2010 Jan
;
15
(
1
):
53
63
. .
2.
Karno
M
,
Golding
JM
,
Sorenson
SB
,
Burnam
MA
.
The epidemiology of obsessive-compulsive disorder in five US communities
.
Arch Gen Psychiatry
.
1988 Dec
;
45
(
12
):
1094
9
. .
3.
Weissman
MM
,
Bland
RC
,
Canino
GJ
,
Greenwald
S
,
Hwu
HG
,
Lee
CK
,
The cross national epidemiology of obsessive compulsive disorder. The Cross National Collaborative Group
.
J Clin Psychiatry
.
1994 May
;
55
(
Suppl
):
5
10
.
4.
Jacobi
F
,
Höfler
M
,
Siegert
J
,
Mack
S
,
Gerschler
A
,
Scholl
L
,
Twelve-month prevalence, comorbidity and correlates of mental disorders in Germany: the Mental Health Module of the German Health Interview and Examination Survey for Adults (DEGS1-MH)
.
Int J Methods Psychiatr Res
.
2014 Sep
;
23
(
3
):
304
19
.
5.
Macy
AS
,
Theo
JN
,
Kaufmann
SC
,
Ghazzaoui
RB
,
Pawlowski
PA
,
Fakhry
HI
,
Quality of life in obsessive compulsive disorder
.
CNS Spectr
.
2013 Feb
;
18
(
1
):
21
33
.
6.
Franklin
ME
,
Foa
EB
.
Treatment of obsessive compulsive disorder
.
Annu Rev Clin Psychol
.
2011
;
7
:
229
43
. .
7.
Olatunji
BO
,
Davis
ML
,
Powers
MB
,
Smits
JA
.
Cognitive-behavioral therapy for obsessive-compulsive disorder: a meta-analysis of treatment outcome and moderators
.
J Psychiatr Res
.
2013 Jan
;
47
(
1
):
33
41
. .
8.
Öst
LG
,
Havnen
A
,
Hansen
B
,
Kvale
G
.
Cognitive behavioral treatments of obsessive-compulsive disorder. A systematic review and meta-analysis of studies published 1993–-2014
.
Clin Psychol Rev
.
2015 Aug
;
40
:
156
69
. .
9.
Rosa-Alcázar
AI
,
Sánchez-Meca
J
,
Gómez-Conesa
A
,
Marín-Martínez
F
.
Psychological treatment of obsessive-compulsive disorder: a meta-analysis
.
Clin Psychol Rev
.
2008 Dec
;
28
(
8
):
1310
25
.
10.
Hunsley
J
,
Elliott
K
,
Therrien
Z
.
The efficacy and effectiveness of psychological treatments for mood, anxiety, and related disorders
.
Canadian Psychol
.
2014
;
55
(
3
):
161
76
.
11.
Shadish
WR
,
Matt
GE
,
Navarro
AM
,
Phillips
G
.
The effects of psychological therapies under clinically representative conditions: a meta-analysis
.
Psychol Bull
.
2000 Jul
;
126
(
4
):
512
29
. .
12.
Seligman
ME
.
The effectiveness of psychotherapy. The Consumer Reports study
.
Am Psychol
.
1995 Dec
;
50
(
12
):
965
74
. .
13.
Jacobson
NS
,
Christensen
A
.
Studying the effectiveness of psychotherapy: how well can clinical trials do the job?
Am Psychol
.
1996 Oct
;
51
(
10
):
1031
9
.
14.
Stewart
RE
,
Chambless
DL
.
Cognitive-behavioral therapy for adult anxiety disorders in clinical practice: a meta-analysis of effectiveness studies
.
J Consult Clin Psychol
.
2009 Aug
;
77
(
4
):
595
606
. .
15.
Hans
E
,
Hiller
W
.
A meta-analysis of nonrandomized effectiveness studies on outpatient cognitive behavioral therapy for adult anxiety disorders
.
Clin Psychol Rev
.
2013 Dec
;
33
(
8
):
954
64
. .
16.
Franklin
ME
,
Abramowitz
JS
,
Kozak
MJ
,
Levitt
JT
,
Foa
EB
.
Effectiveness of exposure and ritual prevention for obsessive-compulsive disorder: randomized compared with nonrandomized samples
.
J Consult Clin Psychol
.
2000 Aug
;
68
(
4
):
594
602
. .
17.
Knopp
J
,
Knowles
S
,
Bee
P
,
Lovell
K
,
Bower
P
.
A systematic review of predictors and moderators of response to psychological therapies in OCD: do we have enough empirical evidence to target treatment?
Clin Psychol Rev
.
2013 Dec
;
33
(
8
):
1067
81
. .
18.
Steketee
G
,
Siev
J
,
Yovel
I
,
Lit
K
,
Wilhelm
S
.
Predictors and moderators of cognitive and behavioral therapy outcomes for OCD: a patient-level mega-analysis of eight sites
.
Behav Ther
.
2019 Jan
;
50
(
1
):
165
76
. .
19.
Fava
GA
,
Rafanelli
C
.
Iatrogenic factors in psychopathology
.
Psychother Psychosom
.
2019 May
;
88
(
3
):
129
40
. .
20.
Baldessarini
RJ
,
Tondo
L
.
Effects of treatment discontinuation in clinical psychopharmacology
.
Psychother Psychosom
.
2019 Mar
;
88
(
2
):
65
70
. .
21.
American Psychiatric Association
.
Diagnostic and statistical manual of mental disorders
. 4th ed.
Washington, DC
:
American Psychiatric Association
;
1994
.
22.
First
MB
,
Gibbon
M
.
The structured clinical interview for DSM-IV axis I disorders (SCID-I) and the structured clinical interview for DSM-IV axis II disorders (SCID-II)
. In:
Hilsenroth
MJ
,
Segal
DL
, editors.
Comprehensive handbook of psychological assessment: personality assessment
.
Hoboken, NJ, USA
:
John Wiley & Sons Inc
;
2004
.
Vol. 2
; p.
134
43
.
23.
Goodman
WK
,
Price
LH
,
Rasmussen
SA
,
Mazure
C
,
Delgado
P
,
Heninger
GR
,
The Yale-Brown Obsessive Compulsive Scale: II. Validity
.
Arch Gen Psychiatry
.
1989 Nov
;
46
(
11
):
1012
6
.
24.
Jones
SH
,
Thornicroft
G
,
Coffey
M
,
Dunn
G
.
A brief mental health outcome scale: reliability and validity of the Global Assessment of Functioning (GAF)
.
Br J Psychiatry
.
1995 May
;
166
(
5
):
654
9
.
25.
Wittmann
WW
,
Lutz
W
,
Steffanowski
A
,
Kriz
D
,
Glahn
EM
,
Völkle
MC
,
Qualitätsmonitoring in der ambulanten Psychotherapie: Modellprojekt der Techniker Krankenkasse – Abschlussbericht [Quality monitoring in outpatient psychotherapy: pilot project of the TK – final report]
.
Hamburg, Germany
:
Techniker Krankenkasse
;
2011
.
26.
Hohagen
F
,
Wahl-Kordon
A
,
Lotz-Rambaldi
W
,
Muche-Borowski
C
.
S3-Leitlinie Zwangsstörungen [S3 guidelines obsessive-compulsive disorder]
.
Heidelberg, Germany
:
Springer-Verlag
;
2015
.
27.
Foa
EB
,
Kozak
MJ
.
Mastery of obsessive-compulsive disorder: a cognitive-behavioural approach therapist guide
. 1st ed.
New York
:
Oxford University Press
;
2004
.
28.
Salkovskis
PM
.
Understanding and treating obsessive-compulsive disorder
.
Behav Res Ther
.
1999 Jul
;
37
(
Suppl 1
:
S29
52
. .
29.
Lakatos
A
,
Reinecker
H
.
Kognitive Verhaltenstherapie bei Zwangsstörungen: Ein Therapiemanual [Cognitive behavioral therapy in obsessive-compulsive disorder: a therapy manual]
. 4th, revised ed.
Göttingen, Germany
:
Hogrefe Verlag
;
2016
.
30.
Hand
I
,
Büttner-Westphal
H
.
Die Yale-Brown Obsessive Compulsive Scale (Y-BOCS): Ein halbstrukturiertes Interview zur Beurteilung des Schweregrades von Denk- und Handlungszwängen [the Yale-Brown obsessive-compulsive scale (Y-BOCS): a semistructured interview for assessing severity of compulsive cognitions and behavior]
.
Verhaltensther
.
1991
;
1
(
3
):
223
5
.
31.
Goodman
WK
,
Price
LH
,
Rasmussen
SA
,
Mazure
C
,
Fleischmann
RL
,
Hill
CL
,
The Yale-Brown Obsessive Compulsive Scale: I. Development, use, and reliability
.
Arch Gen Psychiatry
.
1989 Nov
;
46
(
11
):
1006
11
.
32.
López-Pina
JA
,
Sánchez-Meca
J
,
López-López
JA
,
Marín-Martínez
F
,
Núñez-Núñez
RM
,
Rosa-Alcázar
AI
,
The Yale-Brown Obsessive Compulsive Scale: a reliability generalization meta-analysis
.
Assess
.
2015 Oct
;
22
(
5
):
619
28
.
33.
Foa
EB
,
Huppert
JD
,
Leiberg
S
,
Langner
R
,
Kichic
R
,
Hajcak
G
,
The obsessive-compulsive inventory: development and validation of a short version
.
Psychol Assess
.
2002 Dec
;
14
(
4
):
485
96
.
34.
Gönner
S
,
Leonhart
R
,
Ecker
W
.
The Obsessive-Compulsive Inventory-Revised (OCI-R): validation of the German version in a sample of patients with OCD, anxiety disorders, and depressive disorders
.
J Anxiety Disord
.
2008 May
;
22
(
4
):
734
49
.
35.
Montgomery
SA
,
Åsberg
M
.
A new depression scale designed to be sensitive to change
.
Br J Psychiatry
.
1979 Apr
;
134
:
382
9
. .
36.
Schmidtke
A
,
Fleckenstein
P
,
Moises
W
,
Beckmann
H
.
Untersuchungen zur Reliabilität und Validität einer deutschen Version der Montgomery-Åsberg Depression-Rating Scale (MADRS) [studies of the reliability and validity of the German version of the Montgomery-Åsberg depression rating scale (MADRS)]
.
Schweiz Arch Neurol Psychiatr
.
1988
;
139
(
2
):
51
65
.
37.
Hautzinger
M
,
Keller
F
,
Kühner
C
.
BDI-II. Beck-Depressions-Inventar Revision: Manual
.
Frankfurt, Germany
:
Harcourt Test Services
;
2006
.
38.
Kühner
C
,
Bürger
C
,
Keller
F
,
Hautzinger
M
.
Reliabilität und Validität des revidierten Beck-Depressionsinventars (BDI-II). Befunde aus deutschsprachigen Stichproben [Reliability and validity of the Revised Beck Depression Inventory (BDI-II). Results from German samples]
.
Nervenarzt
.
2007 Jun
;
78
(
6
):
651
6
.
39.
Franke
GH
.
Brief Symptom Inventory (BSI) von L. R. Derogatis (Kurzform der SCL-90-R). Deutsche Version [Brief Symptom Inventory (BSI) from L.R. Derogatis
. (Short form of SCL-90-R). German Version].
Göttingen, Germany
:
Beltz
;
2000
.
40.
Prinz
U
,
Nutzinger
DO
,
Schulz
H
,
Petermann
F
,
Braukhaus
C
,
Andreas
S
.
Comparative psychometric analyses of the SCL-90-R and its short versions in patients with affective disorders
.
BMC Psychiatry
.
2013 Mar
;
13
:
104
. .
41.
Hilsenroth
MJ
,
Ackerman
SJ
,
Blagys
MD
,
Baumann
BD
,
Baity
MR
,
Smith
SR
,
Reliability and validity of DSM-IV axis V
.
Am J Psychiatry
.
2000 Nov
;
157
(
11
):
1858
63
.
42.
Lampert
T
.
Schichtspezifische Unterschiede im Gesundheitszustand und Gesundheitsverhalten [Differences in health status and health behaviour according to social class]
.
Berlin
:
Berliner Zentrum Public Health
;
2005
.
43.
Winkler
J
,
Stolzenberg
H
.
Der Sozialschichtindex im Bundes-Gesundheitssurvey [Social class index in the Federal Health Survey]
.
Gesundheitswesen
.
1999
;
61 Spec No
:
S178
-
83
.
44.
Lampert
T
,
Kroll
LE
.
Die Messung des sozioökonomischen Status in sozialepidemiologischen Studien
. In:
Richter
M
,
Hurrelmann
K
, editors.
Gesundheitliche Ungleichheit [health inequalities]
,
Vol. 2
.
Wiesbaden, Germany
:
VS Verlag für Sozialwissenschaften
;
2009
. p.
309
34
. .
45.
Elsner
B
,
Wolfsberger
F
,
Srp
J
,
Windsheimer
A
,
Becker
L
,
Jacobi
T
,
Long-term stability of benefits of cognitive behavioral therapy for obsessive compulsive disorder depends on symptom remission during treatment
.
Clin Psychol Eur
.
2020 Mar
;
2
(
1
):
1
18
.
46.
Morris
SB
,
DeShon
RP
.
Combining effect size estimates in meta-analysis with repeated measures and independent-groups designs
.
Psychol Methods
.
2002 Mar
;
7
(
1
):
105
25
. .
47.
Mataix-Cols
D
,
Fernández de la Cruz
L
,
Nordsletten
AE
,
Lenhard
F
,
Isomura
K
,
Simpson
HB
.
Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive-compulsive disorder
.
World Psychiatry
.
2016 Feb
;
15
(
1
):
80
1
. .
48.
Launes
G
,
Hagen
K
,
Sunde
T
,
Öst
LG
,
Klovning
I
,
Laukvik
IL
,
A randomized controlled trial of concentrated ERP, self-help and waiting list for obsessive-compulsive disorder: the Bergen 4-day treatment
.
Front Psychol
.
2019 Nov
;
10
:
2500
.
49.
Jacobson
NS
,
Truax
P
.
Clinical significance: a statistical approach to defining meaningful change in psychotherapy research
.
J Consult Clin Psychol
.
1991 Feb
;
59
(
1
):
12
9
. .
50.
Hansen
B
,
Kvale
G
,
Hagen
K
,
Havnen
A
,
Öst
LG
.
The Bergen 4-day treatment for OCD: four years follow-up of concentrated ERP in a clinical mental health setting
.
Cogn Behav Ther
.
2019 Mar
;
48
(
2
):
89
105
. .
51.
Westbrook
D
,
Kirk
J
.
The clinical effectiveness of cognitive behaviour therapy: outcome for a large sample of adults treated in routine practice
.
Behav Res Ther
.
2005 Oct
;
43
(
10
):
1243
61
. [Erratum in: Behav Res Ther 2007 Jul;45(7)]. .
52.
National Institute for Health and Care Excellence
.
Obsessive-compulsive disorder and body dysmorphic disorder: treatment [Internet]
.
London
:
NICE
;
2005
. [updated 2020 June; cited 2021 April 21]. (Clinical Guideline [CG31]). Available from: https://www.nice.org.uk/guidance/cg31.
53.
Katzman
MA
,
Bleau
P
,
Blier
P
,
Chokka
P
,
Kjernisted
K
,
Van Ameringen
M
,
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders
.
BMC Psychiatry
.
2014
;
14
(
Suppl 1
):
S1
.
54.
Koran
LM
,
Hanna
GL
,
Hollander
E
,
Nestadt
G
,
Simpson
HB
;
American Psychiatric Association
.
Practice guideline for the treatment of patients with obsessive-compulsive disorder
.
Am J Psychiatry
.
2007 Jul
;
164
(
Suppl 7
):
5
53
.
55.
DiMauro
J
,
Domingues
J
,
Fernandez
G
,
Tolin
DF
.
Long-term effectiveness of CBT for anxiety disorders in an adult outpatient clinic sample: a follow-up study
.
Behav Res Ther
.
2013 Feb
;
51
(
2
):
82
6
. .
56.
van Oppen
P
,
van Balkom
AJ
,
de Haan
E
,
van Dyck
R
.
Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-up
.
J Clin Psychiatry
.
2005 Nov
;
66
(
11
):
1415
22
. .
57.
von Brachel
R
,
Hirschfeld
G
,
Berner
A
,
Willutzki
U
,
Teismann
T
,
Cwik
JC
,
Long-term effectiveness of cognitive behavioral therapy in routine outpatient care: a 5- to 20-year follow-up study
.
Psychother Psychosom
.
2019 Aug
;
88
(
4
):
225
35
.
58.
Fals-Stewart
W
,
Marks
AP
,
Schafer
J
.
A comparison of behavioral group therapy and individual behavior therapy in treating obsessive-compulsive disorder
.
J Nerv Ment Dis
.
1993 Mar
;
181
(
3
):
189
93
. .
59.
Foa
EB
,
Liebowitz
MR
,
Kozak
MJ
,
Davies
S
,
Campeas
R
,
Franklin
ME
,
Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder
.
Am J Psychiatry
.
2005 Jan
;
162
(
1
):
151
61
.
60.
Hohagen
F
,
Winkelmann
G
,
Rasche-Räuchle
H
,
Hand
I
,
König
A
,
Münchau
N
,
Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study
.
Br J Psychiatry
.
1998
;
173
(
Suppl 35
):
71
8
.
61.
Lambert
MJ
.
Maximizing psychotherapy outcome beyond evidence-based medicine
.
Psychother Psychosom
.
2017 Feb
;
86
(
2
):
80
9
. .
62.
Thiel
N
,
Hertenstein
E
,
Nissen
C
,
Herbst
N
,
Külz
AK
,
Voderholzer
U
.
The effect of personality disorders on treatment outcomes in patients with obsessive-compulsive disorders
.
J Pers Disord
.
2013 Dec
;
27
(
6
):
697
715
. .
63.
Gordon
OM
,
Salkovskis
PM
,
Bream
V
.
The impact of obsessive compulsive personality disorder on cognitive behaviour therapy for obsessive compulsive disorder
.
Behav Cogn Psychother
.
2016 Jul
;
44
(
4
):
444
59
. .
64.
Pinto
A
,
Liebowitz
MR
,
Foa
EB
,
Simpson
HB
.
Obsessive compulsive personality disorder as a predictor of exposure and ritual prevention outcome for obsessive compulsive disorder
.
Behav Res Ther
.
2011 Aug
;
49
(
8
):
453
8
. .
65.
Hilbert
K
,
Jacobi
T
,
Kunas
SL
,
Elsner
B
,
Reuter
B
,
Lueken
U
,
Identifying CBT non-response among OCD outpatients: a machine-learning approach
.
Psychother Res
.
2021 Jan
;
31
(
1
):
52
62
.
66.
Stange
JP
,
MacNamara
A
,
Barnas
O
,
Kennedy
AE
,
Hajcak
G
,
Phan
KL
,
Neural markers of attention to aversive pictures predict response to cognitive behavioral therapy in anxiety and depression
.
Biol Psychol
.
2017 Feb
;
123
:
269
77
.
67.
Bey
K
,
Campos-Martin
R
,
Klawohn
J
,
Reuter
B
,
Grützmann
R
,
Riesel
A
,
Hypermethylation of the oxytocin receptor gene (OXTR) in obsessive-compulsive disorder: further evidence for a biomarker of disease and treatment response
.
Epigenetics
.
2021 Jul
:
1
11
. Online ahead of print.
68.
Eisen
JL
,
Sibrava
NJ
,
Boisseau
CL
,
Mancebo
MC
,
Stout
RL
,
Pinto
A
,
Five-year course of obsessive-compulsive disorder: predictors of remission and relapse
.
J Clin Psychiatry
.
2013
;
74
(
3
):
233
9
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.